Recurrent Third Nerve Paresis with Migraine: A Case Report and Review of the Literature.
Ophthalmoplegia
magnetic resonance imaging
migraine
oculomotor nerve
ophthalmoplegic migraine
Journal
Neuro-ophthalmology (Aeolus Press)
ISSN: 0165-8107
Titre abrégé: Neuroophthalmology
Pays: England
ID NLM: 8408966
Informations de publication
Date de publication:
2024
2024
Historique:
pmc-release:
12
02
2025
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
15
2
2024
Statut:
epublish
Résumé
Ophthalmoplegic migraine (OM), first described by Charcot in 1870, is a disorder characterised by recurrent episodes of migraine associated with ophthalmoplegia. It has been extensively described in children and is rarer in adults. Commonly, the third nerve is affected with pupillary involvement and, more rarely, the fourth or the sixth nerve. OM is now believed to be an inflammatory demyelinating neuropathy. However, in the largest series of OM so far, by Lal et al. it most commonly involved the sixth nerve, started with a crescendo migraine and was accompanied by no enhancement of the cranial nerves. This has led to a rethink about the role of migraine, in the pathogenesis of OM. We describe a 14-year-old boy, with a 10-year history of intermittent headache followed by drooping of right eyelid and diplopia. The current episode started with a migrainous headache, which increased in severity over 3 days, followed by right third nerve paresis with pupillary involvement. Contrast-enhanced magnetic resonance imaging (MRI) of the brain with contrast showed nodular thickening at the root entry zone of the right oculomotor nerve with bright enhancement. The child responded to oral prednisolone, which was tapered over a month. Migraine prophylaxis with propranolol was concurrently added. His repeat MRI brain showed complete disappearance of enhancement of the lesion at 1 year.
Identifiants
pubmed: 38357620
doi: 10.1080/01658107.2023.2276191
pii: 2276191
pmc: PMC10863380
doi:
Types de publication
Case Reports
Langues
eng
Pagination
60-64Informations de copyright
© 2023 Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the authors.